All In Biotech

Drug Trial Radar · NCT07289763

Phase II Randomized, Open-label, Multicenter Clinical Study Evaluating the Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of SHR-2173 Injection in Patients With Primary Membranous Nephropathy

Last checked: Nov 19, 2026Latest source record: Jan 26, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

75

Planned (sponsor's estimate)

Start

Dec 31, 2025

Primary completion

Aug 2027

Study completion Sep 2027

Sponsor

Sponsor type
Industry
First posted
Dec 17, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

To investigate the safety, efficacy, pharmacokinetics, and pharmacodynamics of SHR-2173 injection in patients with primary membranous nephropathy

Conditions

  • Primary Membranous Nephropathy

Interventions

  • SHR-2173 injectionDrug

    SHR-2173 injection, with a total of 8 administrations

  • SHR-2173 injectionDrug

    SHR-2173 injection, with a total of 16 administrations

  • SHR-2173 injectionDrug

    SHR-2173 injection , with a total of 32 administrations

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Adverse eventsTime frame: Week0, 2, 4, 8, 12,16, 20, 24, 28, 32, 36, 40, 48 52
  2. 12-lead ECGTime frame: Week4, 8, 12, 24, 28, 36, 52

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • General hospital of eastern theater command

    Nanjing, Jiangsu, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.